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Introduction: DNA repair and cancer
Mammalian cells exist under constant genotoxic stress 
from both endogenous and exogenous sources. Replica-
tion errors, chemical decay of bases, and reactive oxygen 
species generated during metabolism all contribute to 
DNA damage from within the cell while UV light, 
ionizing radiation (IR), and chemical exposures assault 
the cell’s DNA from outside [1]. To mitigate damage to 
DNA, a number of mechanisms have evolved to repair a 
variety of lesions.
Several processes repair single-stranded DNA damage 
by using the undamaged strand as a template. Base 
excision repair (BER) uses DNA glycosylases to recognize 
and remove non-bulky damaged bases [2]. BER has been 
reviewed in detail previously [3]. Nucleotide excision 
repair (NER) removes bulky distortion in the DNA helix 
and is crucial for the processing of UV-induced damage 
and chemical adducts [4]. Th  e mismatch repair system 
(MMR) removes base-base mismatches and small 
inser  tion or deletion mismatches that can occur during 
replication [5].
Double-strand breaks (DSBs) are repaired by either 
non-homologous end joining (NHEJ) or homologous 
recombination (HR). NHEJ is more prone to deletions 
and other alterations since the fragmented ends are 
processed and re-ligated with no available template to 
ensure accuracy. HR is essentially an error-proof 
mechanism that occurs during the S or G2 phases of the 
cell cycle, when the sister chromatid can provide a 
template for accurate repair [1]. HR is also involved in 
repairing lesions that disrupt the replication fork. A more 
complete review of DSB repair is available elsewhere [6].
Translesion synthesis (TLS) is a DNA tolerance process 
that allows DNA replication to bypass certain lesions (for 
example, thymine dimers and abasic sites) by substituting 
specialized translesion polymerases that function in the 
presence of damaged nucleotides. TLS is involved in the 
removal of interstrand crosslinks (ICLs) [7].
All of the above processes are crucial for a cell’s 
ability to maintain genomic fidelity. Disruptions in 
these path  ways cause a predisposition to accumulate 
DNA damage and, subsequently, mutations. Mutations 
in tumor-suppressor genes, oncogenes, and other 
genes involved in cell survival and growth can lead to 
the development of cancer. Furthermore, there is a 
growing body of evidence that tumors accumulate 
mutations in DNA repair proteins as they progress, 
becoming increasingly malig  nant [8]. In addition to 
playing a central role in the development of cancer, 
DNA repair mechanisms greatly affect the response to 
cytotoxic treatments, including radiation and 
chemotherapy, which target cellular DNA.
Not surprisingly, there is intense interest in DNA 
repair pathways in the ﬁ   eld of oncology. As the 
molecular and genetic details of DNA repair pathways 
and their regulation have become increasingly 
characterized, new opportunities for therapeutic 
intervention have emerged. For a variety of reasons, the 
treatment of breast cancer plays a central role in these 
new areas of development.
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In the early 1990s, BRCA1 and BRCA2 were identiﬁ  ed as 
the tumor-suppressor genes responsible for a signiﬁ  cant 
proportion of hereditary breast cancers. For women who 
are carriers, the estimated risks of developing breast 
cancer and ovarian cancer by age 70 are 40% to 66% and 
13% to 46%, respectively [9]. Carriers also have an 
elevated risk of prostate, pancreatic, and other cancers. 
BRCA2 serves as a co-factor for Rad51, facilitating nuclear 
ﬁ   lament formation and stimulating Rad51-mediated 
recombination reactions required for HR [10-12]. Th  e 
molecular functions of BRCA1 are somewhat less well 
characterized but it appears that BRCA1 is required for 
eﬃ   cient HR, acts in the DNA damage-signaling cascade, 
is involved in chromatin remodeling, and is involved in 
the activation of the Fanconi anemia (FA) pathway [13-17].
Th   e discovery that BRCA1 and BRCA2 are involved in 
HR explains, at least partly, the genomic instability and 
predisposition to cancer that are seen in BRCA carriers. 
Approximately 5% to 10% of breast cancers result from 
loss of heterozygosity at the BRCA locus in BRCA 
mutation carriers. As a result, the tumor cells are most 
deﬁ  cient in HR and are therefore potentially vulnerable 
to therapeutic strategies that target this weakness.
Characteristics of homologous recombination-defi  cient cells
It is well established that cells deﬁ   cient in HR are 
particularly sensitive to DNA crosslinking agents, includ-
ing the platinum-based drugs cisplatin and carboplatin as 
well as mitomycin C, a natural anti-tumor antibiotic. 
Cells deﬁ  cient in BRCA1, BRCA2, XRCC2, and XRCC3 – 
all important components in HR – display this increased 
sensitivity to ICLs [18-20].
ICLs prevent DNA unwinding by covalently linking the 
two DNA strands to each other, thereby disrupting 
replica  tion and transcription. Th   ese lesions are extremely 
toxic to cells and not easily repaired. It appears that the 
combined action of several DNA repair pathways – NER, 
TLS, and HR – in conjunction with the FA pathway is 
required to repair an ICL and that removal of the lesion 
occurs almost exclusively during DNA replication [21].
Th  is cellular sensitivity of HR-deﬁ  cient cells to cross-
linking agents suggests that these drugs may be particu-
larly eﬀ  ective in BRCA-associated tumors. Several studies 
have shown that patients with BRCA-associated ovarian 
cancer have a better prognosis than their sporadic 
counter  parts. In a case series of 71 patients with 
advanced ovarian cancer, including 34 patients with 
BRCA mutations, Cass and colleagues [22] found that the 
patients with BRCA mutations had a signiﬁ  cantly better 
response to platinum-based chemotherapy. Th  e authors 
hypothesized that this increased sensitivity to cisplatin 
was the primary reason for the observed improvement in 
overall survival (OS) [22]. An ongoing phase II trial of 
BRCA-associated breast cancer patients (‘the BRCA 
trial’) aims to discover whether carboplatin is a safer and 
more eﬀ  ective chemotherapy than docetaxel [19].
BRCA-deﬁ  cient cells have also shown hypersensitivity to 
etoposide, a topoisomerase II inhibitor. Etoposide binds to 
topoisomerase II and forms a stable drug-enzyme-DNA 
complex, thereby inhibiting the ﬁ   nal re-ligation step 
required for replication and eventually resulting in a DSB. 
Treszezamsky and colleagues [23] showed that both 
BRCA1- and BRCA2-deﬁ  cient human breast cancer cell 
lines showed an increased sensitivity to etoposide 
compared with their BRCA-complemented counterparts.
Fanconi anemia pathway
FA is a rare x-linked and recessive genetic disorder 
characterized by chromosomal instability, which leads to 
a wide variety of clinical ﬁ  ndings, including bone marrow 
failure, skeletal anomalies and other birth defects, and 
early onset of leukemias and solid tumors. One cellular 
hallmark of FA is hypersensitivity to crosslinking agents, 
including mitomycin C and diepoxybutane [7]. In fact, 
quantiﬁ  cation of chromosomal abnormalities induced by 
these agents is used for clinical diagnosis of FA.
Th   irteen FA genes (designated FANCA [Fanconi 
anemia complementation group A] through FANCN), 
each with a protein product that plays a role in DNA 
repair, have been identiﬁ  ed. Most of the FA proteins are 
involved in the formation of a core complex with 
ubiquitin ligase activity which monoubiquitinates 
FANCD2 and FANCI in response to DNA lesions during 
replication. Th  e FA family members appear to be key 
regulators of DNA repair, thereby helping to maintain 
genetic stability. One primary function of the FA pathway 
appears to be in coordinating several repair pathways – 
NER, TLS, and HR – to remove ICLs, thus explaining the 
sensitivity of Fanconi cells to crosslinking agents. FA 
proteins also interact with several important proteins, 
including ataxia-telangiectasia mutated (ATM), ATM 
and Rad3 related (ATR), and meiotic recombination 11 
(MRE11), which are responsible for genetic instability 
syndromes [24-26]. Furthermore, FA proteins are 
involved in sup  pres  sion of sister chromatid exchanges, 
regulation of cell cycle checkpoints, and cytokinesis [7].
Th   ough discovered independently, BRCA2 and 
FANCD1 have been shown to be the same protein. Th  is 
discovery clariﬁ  ed some of the previously noted simi-
larities and interactions between the BRCA proteins and 
the FA family of proteins, including the shared hyper-
sensitivity to mitomycin C and the ﬁ  nding that targeted 
inactivation of the BRCA2 protein in mice produced an 
FA-like phenotype [27]. Although mechanistic details 
have yet to be worked out, there is accumulating evidence 
that the BRCA and FA DNA repair pathways are inti-
mately related.
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ICLs, the status of the FA pathway is an important 
determinant of sensitivity to cisplatin and other cross-
linking agents. In fact, reactivation of the FA pathway 
appears to be a mechanism by which tumors acquire 
resistance to cisplatin [28]. Conversely, it has been shown 
that disruption of the FA pathway leads to increased 
cisplatin sensitivity in tumor cell lines. Th  is has been 
accomplished by using a gene therapy approach [29] or 
by inhibiting the monoubiquitination of FANCD2 by a 
small-molecule inhibitor such as curcumin [30].
Mismatch repair system-defi  cient tumors
Genetic defects in the MMR pathway are well known to 
cause microsatellite instability and predispose patients to 
hereditary non-polyposis colorectal cancers (HNPCCs) 
and other HNPCC spectrum tumors, including endo-
metrial, gastric, and ovarian cancer. Th   ere are some early 
data suggesting that epigenetic silencing of the MMR 
genes may contribute to the development of sporadic 
breast cancers. A substantial proportion of sporadic breast 
cancers (24% to 46%) contain hypermethylated promoters 
at hMLH1 and hMSH2 and this may be associated with 
more advanced breast cancers and reduced OS [31-34].
In contrast to other DNA repair systems (for example, 
HR and BER), a functional MMR pathway actually 
enhances the cytotoxicity of a variety of chemo  thera  peutic 
agents. Following administration of chemothera  peutic 
agents such as temozolomide (TMZ) or 6-thioguanine 
(6-TG), MMR-proﬁ  cient cells repeatedly and unsuccess-
fully attempt to process chemically induced mispairs. 
Th  is futile cycling of the MMR pathway is believed to 
signal a G2 checkpoint arrest and apoptosis. Damage 
induced by IR is also recognized by MMR, resulting in 
MMR-mediated cytotoxicity, which is most pronounced 
at low dose rates [35,36]. Th  us,  MMR-deﬁ  cient cells can 
be resistant to both chemotherapy and radiotherapy.
Currently, the use of iododeoxyuridine (IUdR) and other 
radiosensitizing agents that preferentially accumu  late in 
MMR-deﬁ   cient cells is being investigated as a way to 
selectively target these therapy-resistant cells. In an attempt 
to maximize the therapeutic ratio, computational models 
based on extensive experimental data are being used to 
predict the optimal dose of IUdR and timing of IR [5]. In 
addition, knowledge of resistance mechanisms to speciﬁ  c 
chemotherapeutic agents should help guide drug selection.
PARP inhibition, base excision repair, and synthetic 
lethality
Poly(ADP-ribose) polymerase 1 (PARP1) is the most 
well-characterized member of the PARP superfamily. An 
abundant nuclear protein, PARP1 is involved in a wide 
variety of cellular processes ranging from inﬂ  ammation 
to apoptosis and, importantly, BER. PARP1 contains 
zinc-ﬁ  nger motifs that allow it to detect and bind to sites 
of single-stranded DNA damage. Using NAD+ as a 
substrate, PARP1 catalyzes the addition of ADP-ribose 
polymer sidechains to itself, DNA ligase III, DNA poly-
merase-β, XRCC1, and other repair components, thereby 
recruiting and regulating the eﬀ  ectors of BER [37,38]. 
Th  e presence of PARP1 has been shown to be required 
for eﬃ     cient functioning of BER [39,40]. A variety of 
molecules, most of which mimic the nicotinamide moiety 
of NAD+, have been developed to inhibit the action of 
PARP1, thereby inhibiting eﬃ     cient BER [41]. Th  ese 
agents have shown promising potential both as mono-
therapy for patients with HR-deﬁ   cient tumors and in 
potentiating eﬀ   ects of traditional cytotoxic agents, 
includ  ing chemotherapy and radiotherapy.
In 2005, two groups published the ﬁ  nding that BRCA-
deﬁ  cient cells are sensitive to agents that inhibit PARP1 
[42,43]. Th   is discovery generated intense interest, in part 
because of the potentially large therapeutic window that 
exists in a situation in which synthetic lethality is present. 
Synthetic lethality occurs when two lesions that are 
individually non-lethal become lethal when combined 
(Figure 1). In this particular situation, the HR-deﬁ  cient 
BRCA mutant cells become highly dependent on other 
DNA repair pathways, including BER, that help prevent 
development of DSBs in order to compensate for their 
inability to repair DSB in an error-free manner. When 
PARP1 and therefore BER are inhibited, the unrepaired 
single-strand breaks (SSBs) eventually cause the collapse 
of the replication fork and become DSBs, overwhelming 
the cell’s repair machinery and leading to cell death. Th  e 
non-tumor cells are better able to tolerate the PARP 
inhibition because their HR machinery is intact.
Synthetic lethality represents a new strategy for the 
development of anti-cancer drugs. Traditional chemo-
thera  peutic agents are relatively non-selective, often 
target  ing rapidly dividing cells, which include both tumor 
and some normal cells. Using a synthetic lethality 
approach, screening programs can be designed to identify 
target genes that, when mutated or inhibited, lead to the 
death of cancer cells that already carry additional 
alterations in diﬀ  erent genes [44,45]. Normal cells should 
be spared since it is the combination of a drug-induced 
alteration with a cancer-related alteration that is lethal.
DNA repair defects, epigenetic inactivation, and 
the concept of ‘BRCAness’
Although germline mutations in BRCA1 or BRCA2 
account for 5% to 10% of breast cancers, these loci are 
rarely mutated in sporadic tumors. Nonetheless, there 
are gene expression proﬁ  les as well as clinical and patho-
logical phenotypes of some sporadic tumors that closely 
resemble those of BRCA-associated tumors. Using gene 
expression microarray analysis, sporadic tumors can be 
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tumors, expresses high levels of myoepithelial cyto  keratins 
found in the outer basal layer of cells in a normal breast 
duct. Th   ese tumors share a similar gene expression proﬁ  le 
with BRCA1-associated tumors, suggesting a common 
etiology. Furthermore, both groups tend to be estrogen 
receptor-negative and human epidermal growth factor 
receptor 2/neu (HER2)-negative, have a higher mitotic 
count, show lymphocytic inﬁ  ltration, and appear to have a 
‘pushing margin’ pattern of invasion at the tumor edge [46].
BRCA1 promoter methylation
While BRCA1 and BRCA2 are infrequently mutated in 
sporadic tumors, there is increasing evidence for 
epi  genetic mechanisms that result in silencing of DNA 
repair genes. Th  e most well-characterized epigenetic 
mecha  nism is that of BRCA1 promoter hypermethylation 
leading to undetectable BRCA1 expression. Gene promo-
ters frequently contain CpG dinucleotide islands, which, 
under normal conditions, are unmethylated. Methylation 
of these cytosine residues leads to silencing of trans-
cription. Abnormal methylation of the BRCA1 promoter 
is found in 11% to 14% of sporadic breast tumors [46].
FANCF promoter methylation
Another potentially important mechanism of epigenetic 
inactivation of repair pathways is methylation of the 
FANCF promoter. FANCF is a member of the Fanconi 
Figure 1. Example of synthetic lethality: PARP inhibition in cells defi  cient in homologous recombination (HR). (a) In normal cells, repair 
pathways, including base excision repair (BER) and HR, are intact. Single-strand breaks (SSBs) are readily repaired by BER, with the participation of 
PARP1, and double-strand breaks (DSBs) are reliably repaired by HR, with the participation of BRCA1 and BRCA2. (b) Cells with mutations in BRCA1 
or BRCA2 are defi  cient in HR. Other repair pathways, including the BER pathway, are able to minimize the number of lesions that become DSBs. 
(c) Normal cells treated with PARP inhibitors may become defi  cient in BER. Therefore, more SSBs go unrepaired. During replication, the replication 
fork may stall, resulting in the conversion of SSBs into DSBs. HR can repair these DSBs in an error-free manner. (d) When PARP inhibitors are delivered 
to cells defi  cient in HR (for example, BRCA-mutated cells), synthetic lethality can result. Inhibition of BER by PARP inhibitors results in the conversion 
of unrepaired SSBs into DSBs. These DSBs cannot be repaired by HR in an error-free manner and can therefore result in cell death. PARP, poly(ADP-
ribose) polymerase.
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FANCD2-I ubiquitination. FA patients harboring homo-
zy  gous mutations to FANCF display extreme sensi  tivity 
to DNA crosslinking agents. It appears that FANCF 
methylation is a frequent mechanism by which sporadic 
tumors inactivate the BRCA/FA pathways. FANCF 
methyl  ation is found in approximately 17% of sporadic 
breast cancers and has also been detected in ovarian, 
non-small cell lung cancer (NSCLC) and cervical cancer 
[46]. High sensitivity to cisplatin has been found in two 
ovarian cancer cell lines lacking expression of FANCF 
due to FANCF promoter methylation [28].
EMSY amplifi  cation
While hypermethylation of the BRCA2 promoter region 
does not appear to contribute to the development of 
sporadic breast cancers, there is evidence that BRCA2 
transcription can be silenced by ampliﬁ   cation of the 
EMSY gene. EMSY is located on 11q13 and has been 
found to be ampliﬁ  ed in 13% of sporadic breast cancers. 
Th  e EMSY protein product binds to BRCA2 at exon 3, 
causing silencing of BRCA2 transcription [46]. Recent 
data suggest that EMSY ampliﬁ  cation may be associated 
with reduced OS [47].
‘BRCAness’
Th   e sensitivity of BRCA-deﬁ  cient cells to PARP inhibitors 
is likely due to the underlying defect in HR. Th  is was 
illustrated by McCabe and colleagues [48], who showed 
that cells deﬁ  cient in a variety of proteins involved in 
HR – including RAD51, RAD54, DSS1, RPA1, NBS, ATR, 
ATM, CHK1, CHK2, FANCD2, FANCA, and FANCC – 
displayed sensitivity to PARP inhibition. Th  us, cancer 
cells with alterations in these and other proteins might 
also be included in the group of tumors displaying 
properties of ‘BRCAness’.
Th   e clinical signiﬁ  cance of ‘BRCAness’ lies in the idea 
that, taken together, a substantial proportion of sporadic 
breast cancers may harbor defects in repair pathways. 
Like BRCA-associated tumors, these ‘BRCAness’ tumors 
might be susceptible to synthetic lethality approaches 
involving PARP inhibitors or other inhibitors of BER. 
Alternatively, these tumors might be better treated with 
crosslinking chemotherapeutic agents rather than 
standard taxanes.
A number of clinical trials that aim to address these 
issues are under way. Various PARP inhibitors are 
currently being tested alone or in combination with 
chemotherapeutic agents in the treatment of triple-
negative, BRCA-deﬁ  cient, and metastatic breast cancers. 
Chemotherapeutic agents being tested include carboplatin 
and cisplatin, topotecan, gemcitabine, doxil, TMZ, and 
paclitaxel. Th   e results of these many clinical trials will help 
to clarify the therapeutic potential of these strategies.
Screening approaches
Given the mechanistic heterogeneity of the diﬀ  erent 
breast cancers harboring defects in DNA repair, novel 
screening approaches could help in determining which 
patients may beneﬁ  t from PARP inhibition and similar 
therapies. Recently, Willers and colleagues [49] reported 
on a pilot study of an ex vivo biomarker assay for several 
DNA repair protein foci (BRCA1, FANCD2, and RAD51) 
with the goal of identifying the BRCA1-deﬁ  cient pheno-
type, regardless of the underlying mechanism leading to 
the HR deﬁ  ciency. Core biopsies from seven previously 
untreated breast cancers were treated with 8 gray (Gy) of 
x-irradiation with corresponding untreated controls from 
the same tumor. After incubation, sectioning, and stain-
ing of the breast biopsy specimens, RAD51, FANCD2, 
and BRCA1 foci were successfully detected. Four of the 
seven tumors displayed a BRCA1 defect with corres-
ponding impairment of FANCD2 and RAD51 foci as well 
[49]. Of interest, three of the four tumors with a BRCA1 
defect were triple-negative, lending support to the idea of 
‘BRCAness’ [50]. Screening biopsy tissue for potential 
therapeutic response is a compelling idea that may play 
an important role in selection of therapies.
Targeting DNA damage signaling and checkpoints
A signiﬁ  cant amount of work has gone into targeting the 
DNA damage-sensing pathways and cell cycle check-
points. Th   e phosphatidylinositol-3-kinase-related kinases 
(PIKKs), including ATM, ATR, and DNA-dependent 
protein kinase (DNA-PK), have emerged as promising 
targets for small-molecule inhibitors. Th   is topic is 
beyond the scope of this article but has been reviewed in 
detail elsewhere [50,51].
Early clinical development of PARP inhibitors
PARP inhibitors as monotherapy
Several phase I and II trials using PARP inhibitors for 
patients with breast, ovarian, and a variety of other 
malig  nancies are currently under way (Table 1). Fong and 
colleagues [52] recently published results from a phase I 
trial of olaparib – a potent, orally active PARP inhibitor – 
administered as monotherapy. Sixty patients with 
advanced solid tumors, 22 of whom were carriers of a 
BRCA1 or BRCA2 mutation, were enrolled and treated. 
Dose escalation was performed using a modiﬁ  ed 
accelerated-titration design. Once the maximum 
tolerated dose was determined, a cohort of only BRCA 
carriers was enrolled [52].
Olaparib was found to be absorbed rapidly with a peak 
plasma concentration between 1 and 3 hours after 
adminis  tration. Terminal-elimination half-life was 5 to 
7 hours, which led the investigators to choose a twice-
daily dosing scheme. PARP inhibition was conﬁ  rmed in 
peripheral blood mononuclear cells (PBMCs) and by 
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biopsy specimens collected before initiation of olaparib 
and after 8 days of treatment.
Overall, olaparib was well tolerated and resulted in less 
toxicity than standard chemotherapeutic agents. Th  ree  of 
sixty patients experienced toxicity of grade 3 or higher, 
including grade 3 mood alteration and fatigue, grade 4 
thrombocytopenia, and grade 3 somnolence. Otherwise, 
adverse events (AEs) were largely grade 1 or 2, gastro-
intestinal (GI)-related (28% nausea, 18% vomiting, and 
12% dysgeusia) or general disorders (28% fatigue and 12% 
anorexia).
Although this was a phase I trial, some clinical response 
data were reported. Twelve of the nineteen evaluable 
patients with a BRCA1 or BRCA2 mutation and ovarian, 
breast, or prostate cancer had a clinical beneﬁ  t,  with 
radiologic or tumor-marker responses or disease stabili-
za  tion of at least 4 months. Nine BRCA carriers had a 
response according to Response Evaluation Criteria in Solid 
Tumors (RECIST). No patients without known BRCA 
mutations experienced objective anti-tumor responses.
BSI-201, a small-molecule inhibitor of PARP, has also 
been tested in a phase I dose-escalation trial as mono-
therapy for patients with refractory, advanced solid 
tumors. PARP inhibition was conﬁ  rmed in PBMCs. All 
doses were well tolerated, and no maximum tolerated 
dose was identiﬁ  ed. Again, the most common observed 
AEs were GI-related (39% of AEs) or general disorders 
(21% of AEs). Six of the twenty-three subjects, all of 
whom had been heavily treated previously, achieved 
stable disease for 2 months or more [53].
PARP inhibitors in combination with cytotoxic agents
By inhibiting BER, PARP inhibitors have the potential to 
enhance the lethality of cytotoxic agents, especially in 
tumor cells that already have defects in DNA repair 
pathways. Several chemotherapeutic agents, in combina-
tion with PARP inhibition, have shown promising pre-
clinical results (Table 2).
Preclinical
Temozolomide
Th   e mechanism of action of the methylating agent, TMZ, 
makes it a particularly attractive agent to use in combi-
nation with PARP inhibition. Although the predominant 
methylation products of TMZ are N7-methylguanine and 
N3-methyladenine, these lesions are repaired very 
eﬃ   ciently by BER and so do not normally contribute to 
cytotoxicity. By inhibiting BER, PARP inhibitors have the 
potential to increase the number of cytotoxic lesions 
generated. In addition, TMZ resistance frequently 
develops due to eﬃ     cient repair of toxic O6-methyl-
guanine adducts or due to defects in the MMR, which, 
when functional, contributes to TMZ cell killing. Indeed, 
the PARP inhibitor, AG14361, has been shown to restore 
sensitivity to TMZ in mismatch repair-deﬁ  cient human 
colon and ovarian cancer cells [54]. Another PARP 
inhibitor, INO-1001, restored sensitivity to TMZ in 
xenografts of glioblastoma multiforme (GBM) tumor 
cells deﬁ  cient in mismatch repair [55].
Several preclinical studies have shown promising 
synergy between TMZ and PARP inhibition in a variety of 
human cancer cell lines and murine xenograft models. 
Using an SW620 colorectal cell murine xenograft model, 
Calabrese and colleagues [56] showed that, when added to 
TMZ, AG14361 increased cytotoxicity fourfold to ﬁ  vefold 
in LoVo colorectal cancer cell lines. Furthermore, using an 
SW620 colorectal cell murine xenograft model, a 100% 
complete remission rate was achieved when AG14361 was 
added to TMZ [56]. ABT-888 has shown potentiation of 
TMZ in HCT116 colorectal and other cancer cells [57]. 
CEP-6800, a novel inhibitor of both PARP1 and PARP2, in 
combination with TMZ showed 100% tumor regression in 
U251MG human glioblastoma xenografts in nude mice [58].
Table 1. PARP inhibitors currently in clinical trials
Agent  Route  Phase of development  Comments
ABT-888  Oral  Phase 2  Being tested in combination with TMZ for patients with metastatic breast cancer and 
     metastatic  melanoma
AG014699  Intravenous  Phase 2  Being tested in locally advanced or metastatic BRCA-associated breast or ovarian cancer
AZD2281 (olaparib)  Oral  Phase 2  Being tested in multiple phase 2 trials for BRCA-associated advanced breast cancer and 
     ovarian  cancer
BSI-201  Intravenous  Phase 2  Being tested in neoadjuvant setting in combination with gemcitabine plus carboplatin for 
      patients with triple-negative breast cancer
CEP-9722  Subcutaneous  Phase 1  Being tested as a single agent and in combination with TMZ in patients with advanced 
     solid  tumors
INO-1001  Intravenous  Phase 1B  Recently completed phase 1B trial in combination with TMZ for patients with stage III or IV 
     melanoma
MK4827  Oral  Phase 1  Being tested in phase 1 for patients with advanced solid tumors
PARP, poly(ADP-ribose) polymerase; TMZ, temozolomide.
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Recent work in our laboratory indicates that alternative 
means of BER inhibition similarly potentiate the eﬀ  ects 
of TMZ. We investigated the eﬀ  ects of lithocholic acid, 
an inhibitor of the key BER enzyme DNA polymerase β, 
in combination with TMZ. Th  e two agents displayed 
synergism when given together in BRCA2-complemented 
cell lines. Furthermore, when the two agents were co-
administered in BRCA2-deﬁ   cient cells, the degree of 
synergism was increased [59]. Th   e mechanism of 
potentiation appears to be similar to that seen with PARP 
inhibition, namely, persistent single-stranded DNA 
breaks incompletely repaired by BER being converted 
into DSB during replication, thereby leading to cell death.
Topoisomerase inhibitors
Th  e combination of PARP inhibitors with the topo-
isomerase I inhibitors has also been explored. Early work 
showed that camptothecin cytotoxicity was potentiated 
by PARP inhibition [60]. Further work by Delaney and 
colleagues [61] showed that topotecan cytotoxicity was 
enhanced in a variety of human cancer cell lines, but this 
eﬀ  ect did not hold true for etoposide, a topoisomerase II 
inhibitor.
Ionizing radiation
IR induces cell killing primarily through the induction of 
DSBs. Several preclinical trials have shown that PARP 
inhibition can enhance the lethality of IR. Calabrese and 
colleagues [56] administered AG14361 30 minutes prior 
to 2 Gy of x-irradiation to mice with colorectal cancer 
xenografts and found that the addition of AG14361 
increased anti-tumor activity by approximately twofold. 
ABT-888 has been shown to potentiate fractionated 
radiotherapy in preclinical lung cancer and colon cancer 
murine models [62,63]. Brock and colleagues [64] treated 
a murine sarcoma cell line with a single fraction of 
radiation with and without INO-1001 and found that 
these cells were radiosensitized by PARP inhibition with 
an enhancement ratio of 1.7.
To our knowledge, no clinical trials that combine IR 
with PARP inhibition are currently under way. Th  e key 
clinical question that remains to be answered is to what 
extent PARP inhibition will diﬀ  erentially  increase 
lethality to tumor cells over normal cells, thereby 
resulting in an improved thera  peutic ratio.
Clinical trials
Th   e therapeutic strategy of PARP inhibition in 
combination with chemotherapy is currently being 
investi  gated in several clinical trials, some of which have 
been completed. Plummer and colleagues [65] performed 
a phase I study investigating AG014699, a tricyclic indole 
administered intravenously, with TMZ in patients with 
advanced solid tumors. In the ﬁ   rst phase of the trial, 
AG014699 was dose-escalated to establish the PARP 
inhibitory dose (PID) in peripheral blood lymphocytes 
(PBLs) with no dose-limiting toxicity observed. In the 
second phase, a cohort of metastatic melanoma patients 
received AG014699 at the previously established PID 
while the TMZ dose was escalated up to 200 mg/m2 [65].
Th  e combination of AG014699 and TMZ was well 
tolerated, with no observed toxicity attributable to 
AG014699 alone. Minimal myelosuppression was ob-
served using the PID of AG014699 and 200 mg/m2 TMZ. 
Th  e dose-toxicity curve appeared to be steep, with 
myelosuppression observed when either the AG014699 
dose or the TMZ dose was increased. Clinical beneﬁ  t was 
observed in several patients with one documented 
complete response and one partial response in two 
chemo  naive patients with metastatic melanoma.
Early results from a phase II trial examining AG014699 
and TMZ in patients with chemonaive metastatic mela-
noma have also been reported. More myelosuppression 
was observed compared with the phase I trial, with 12% 
of patients experiencing grade 4 thrombocytopenia and 
15% experiencing grade 4 neutropenia. One patient died 
from febrile neutropenia after one cycle, and 12 patients 
required dose reduction of TMZ. Encouraging activity 
was seen as several patients achieved partial responses or 
Table 2. Preclinical testing of PARP inhibitors and other inhibitors of base excision repair
Agent  Mechanism  Cancer cell lines/tumor models  Agents potentiated  References
ABT-888  PARP inhibition  Breast, lung, ovarian, colon, melanoma, glioma  TMZ, cisplatin, carboplatin, irinotecan,   [57,62,63]
     cyclophosphamide,  IR
AG14361  PARP inhibition  Lung, colorectal  TMZ, topotecan, irinotecan, IR  [56]
CEP-6800  PARP inhibition  Colon, GBM, NSCLC  TMZ, irinotecan, cisplatin  [58]
CEP-8983  PARP inhibition  GBM, colon, rhabdomyosarcoma, neuroblastoma  TMZ, camptothecin, irinotecan  [85]
INO-1001  PARP inhibition  Breast, GBM, sarcoma  TMZ, doxorubicin, IR  [55,64]
Lithocholic acid  DNA pol-β inhibition  BRCA2-defi  cient Chinese hamster ovary cells  TMZ  [59]
Methoxyamine  AP site binding  Colon  TMZ, BCNU  [68]
AP, apurininc/pyrimidinic; BCNU, 1,3-bis(chloroethyl)-1-nitrosourea; GBM, glioblastoma multiforme; IR, ionizing radiation; NSCLC, nucleotide excision repair; PARP, 
poly(ADP-ribose) polymerase; TMZ, temozolomide. 
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to evaluate most of the patients [66].
BSI-201 has been tested in combination with topo-
tecan, gemcitabine, TMZ, and carboplatin/paclitaxel in a 
phase IB trial involving patients with advanced solid 
tumors. BSI-201 was well tolerated in all combinations 
and at all doses tested. No serious AEs were attributed to 
the study drug. One patient with ovarian cancer obtained 
a complete response at 6 months, and several other 
patients with a variety of primary tumors achieved partial 
responses [53]. Given these encouraging results, BSI-201 
is being tested in several phase II clinical trials, including 
as part of a neoadjuvant regimen with gemcitabine and 
carboplatin for triple-negative breast cancer.
Several other inhibitors of BER are being tested in 
combination with TMZ in phase I trials. INO-1001, a 
highly potent PARP inhibitor, was recently tested with 
TMZ in a phase IB trial for patients with unresectable 
stage III/IV melanoma. Dose-limiting toxicities of the 
combination were myelosuppression and hepatic toxicity, 
manifest by elevated transaminases that returned to 
normal upon withdrawal of the medication. Th  e  median 
time to progression was 2.2 months, and of the 12 
evaluable patients, one had a partial response and four 
had stable disease [67]. Methoxyamine is a small 
molecule that inhibits BER by binding directly to 
apurinic/apyrimidinic sites and preventing their 
processing by APE-1 [68]. Methoxyamine and TMZ are 
currently being tested in combination in a phase I trial 
for patients with advanced solid tumors.
Mechanisms of resistance
Hypoxia
Hypoxic cells are known to be more resistant to radio-
therapy and chemotherapy than normoxic cells are [69]. 
Hypoxic cell populations within tumors are believed to 
be a signiﬁ   cant reason for radiotherapy failures, and, 
indeed, the clinical targeting of hypoxic cell populations 
is associated with improved locoregional control and OS 
[70]. Not only does hypoxia mediate resistance to therapy, 
it promotes genetic instability and aggressive muta-
genesis, in part by impairing DNA repair pathways in 
tumor cells.
Acute hypoxia
Hypoxia appears to decrease radiation damage by multiple 
mechanisms. Th  e classic ‘oxygen ﬁ  xation  hypothesis’ 
holds that DNA lesions produced by x-rays in the 
presence of oxygen cannot be chemically restored and 
are therefore more lethal to cells [71]. Recent data 
support the idea that, under acutely hypoxic conditions, 
the check  point kinases ATM and ATR are activated and 
limit DNA damage through cell cycle arrest [72]. Th  e 
coordinated cellular response to hypoxic stress in 
conjunction with the damage-potentiating role of oxygen 
following IR may largely explain the classic ﬁ  nding of 
hypoxic radioresistance. Interestingly, it has been shown 
that the PARP inhibitor ABT-888 can radiosensitize 
acutely hypoxic human prostate and NSCLC cell lines to 
a level similar to that of oxic radiosensitivity [73]. Th  e 
mecha  nism for this radiosensitization may be related to 
trans  criptional downregulation of HR by PARP inhibition 
[74].
Chronic hypoxia
Following the initial, acute DNA damage response, it 
appears that a chronic hypoxic response develops 
whereby important genes in the MMR and HR pathways – 
including MLH1, MSH2, BRCA1, and Rad51 – are down-
regulated [75-79]. Chan and colleagues [80] recently 
found that chronically hypoxic cells display increased 
sensitivity to crosslinking agents cisplatin and mitomycin 
C. Given that increased sensitivity to crosslinking agents 
is a hallmark of HR-deﬁ  cient cells, these ﬁ  ndings support 
the idea that radioresistance during chronic hypoxia is 
decreased compared with acute hypoxia due to 
downregulation of repair pathways. MicroRNAs – small, 
non-protein-coding RNAs that bind to and regulate 
mRNAs – also appear to be important participants in the 
regulation of DNA repair in response to chronic hypoxia 
[81]. As the details of microRNA regulatory mechanisms 
emerge, they may reveal therapeutic opportunities to be 
exploited.
Secondary mutations
Recent discoveries are shedding light on how BRCA-
mutated cancer cells acquire resistance to therapies. 
While ovarian cancers with a mutation in BRCA1  or 
BRCA2 are generally sensitive to cisplatin or carboplatin, 
these cancers eventually become resistant. Sakai and 
colleagues [82] recently showed that secondary intragenic 
mutations in BRCA2 that restore the wild-type BRCA2 
reading frame can mediate resistance to cisplatin. 
Similarly, Edwards and colleagues [83] showed that intra-
genic deletions causing restoration of the open reading 
frame in BRCA2 mutant cells can also result in resistance 
to PARP inhibition. Th  e same mechanism has been 
implicated in the development of platinum resistance in 
BRCA1-mutated ovarian carcinomas [84]. Ironically, the 
HR deﬁ  ciency that is being targeted therapeutically also 
increases the likelihood of additional mutations, some of 
which will restore the open reading frame and thereby 
restore BRCA function.
Conclusions
DNA repair pathways play a central role in cancer, both 
in the development of cancer and in the response to 
therapies. Th   e elucidation of the molecular mechanisms 
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Page 8 of 11of DNA repair and the discovery that tumors are 
frequently repair-deﬁ  cient provide a therapeutic oppor-
tunity to selectively target this weakness, especially in 
breast cancers. In BRCA-associated breast cancer, the 
inhibition of BER with agents such as the PARP inhibitors 
may provide an eﬀ   ective synthetic lethality approach 
resulting in tumor cell death with minimal toxicity to 
normal tissues. Furthermore, a substantial proportion of 
sporadic breast cancers, including the therapeutically 
challenging basal-like subset, may have similar repair 
pathway deﬁ  ciencies that make them susceptible to these 
agents. Inhibiting DNA repair may also enhance the 
eﬀ  ectiveness of cytotoxic therapies such as chemotherapy 
and radiation therapy, although it remains to be seen to 
what extent this increased cytotoxicity will diﬀ  erentially 
aﬀ   ect tumor cells in patients. Knowledge of the 
mechanisms of DNA damage and repair may help to 
guide selection of chemotherapeutic agents and also may 
help elucidate mechanisms of resistance. Th  e role of 
hypoxia in the regulation of DNA repair is still under 
investigation and may oﬀ   er additional therapeutic 
targets.
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